Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
Status:
Completed
Trial end date:
2006-05-15
Target enrollment:
Participant gender:
Summary
Primary Objectives:
1. (Phase I) To establish the maximum tolerated dose and dose-limiting toxicities of the
combination of OSI-774 (Tarceva™) and rhuMAb VEGF (Avastin™) in patients with advanced
Non-small-cell lung carcinoma (NSCLC).
2. (Phase II) To assess response rate and tolerability of the regimen at the dose level
established in the phase I portion of this study.
Secondary Objectives:
1. (Phase I and II) To evaluate the pharmacokinetic interaction between the combination.
2. (Phase I) To establish a phase II regimen of the OSI-774/ rhuMAb VEGF combination, for
further study alone or in combination with cytotoxic chemotherapy.